spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  malignant melanoma 

 HSMN NewsFeed - 1 May 2020
SciBase Receives FDA Approval for Nevisense 3.0
Devices Dermatology Oncology FDA
 HSMN NewsFeed - 17 May 2018
ImaginAb Reconstitutes Scientific Advisory Board
Biopharmaceuticals Oncology Radiology Personnel
 HSMN NewsFeed - 6 Sep 2017
RXi Pharmaceuticals Announces Completion of Enrollment of Phase 2 Clinical Trial with Samcyprone for Cutaneous Warts
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 27 Oct 2016
The Myriad myPath(R) Melanoma Test Effectively Diagnosed Patients in the Largest Outcomes-Based Study for a Melanoma Diagnostic
Diagnostics Dermatology Oncology
 HSMN NewsFeed - 9 Dec 2015
SciBase Submits Application for Pre-Market Approval to FDA
Devices Dermatology Oncology FDA
 HSMN NewsFeed - 7 Nov 2014
Myriad myPath(TM) Melanoma Improves Diagnosis and Treatment Plans
Diagnostics Dermatology Oncology
 HSMN NewsFeed - 9 Sep 2014
Myriad myPath(TM) Melanoma Test Reduced Indeterminate Cases by 76 Percent and Changed Treatment in 35 Percent of Cases
Diagnostics Oncology
 HSMN NewsFeed - 2 Jun 2014
Myriad myPath(TM) Melanoma Test Improves the Reliability of Melanoma Diagnosis
Diagnostics Dermatology Oncology
 HSMN NewsFeed - 13 Jan 2014
Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Nov 2013
Myriad Genetics Launches myPath(TM) Melanoma Diagnostic Test
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 14 Oct 2013
Myriad's myPath(TM) Melanoma Test is Highly Effective in Verification Study
Diagnostics Oncology Dermatology
 HSMN NewsFeed - 5 Sep 2013
GSK’s MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Melanoma Misses First Co-Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Aug 2012
Pharmalucence Announces FDA Approval and Orphan Drug Designation for Use of Sulfur Colloid Injection to Locate Lymph Nodes in Malignant Melanoma Patients
Biopharmaceuticals Diagnostics Oncology FDA
 HSMN NewsFeed - 2 Nov 2011
MELA Sciences Announces FDA Approval for MelaFind(R)
Devices Oncology Dermatology FDA
 HSMN NewsFeed - 13 Dec 2010
Lilly Suspends Phase III Trial in Metastatic Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2010
Myriad Acquires Novel Technology From Melanoma Diagnostics
Diagnostics Oncology Acquisitions
 HSMN NewsFeed - 15 Oct 2010
Celgene Completes Acquisition of Abraxis
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 29 Jul 2010
Abraxis BioScience and Specialised Therapeutics Announce Approval to Market ABRAXANE for Metastatic Breast Cancer in New Zealand
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Jul 2010
ABRAXANE(R) Approved for Marketing in Japan for Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 30 Jun 2010
Celgene to Acquire Abraxis BioScience Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 8 Jun 2010
New ABRAXANE(R) Data Demonstrates Potential in Patients with Advanced and Malignant Melanoma, Among the Toughest Cancers to Treat
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Mar 2010
ABRAXANE Meets Primary Endpoint in Phase 3 Trial for Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Nov 2009
ABRAXANE(R) Receives Orphan Drug Status for the Treatment of Pancreatic Cancer and Stage IIB-IV Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Oct 2009
FDA Advisory Committee Recommends Approval of PEGINTRON(R) for the Adjuvant Treatment of Stage III Malignant Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Aug 2009
Results from a Phase 2 Study of ABRAXANE(R) In Combination With Carboplatin Show Clinical Activity in the First Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Jul 2009
NeoGenomics Enters into Strategic Supply Agreement with Abbott for Development of a Melanoma Cancer Test
Diagnostics Oncology
 HSMN NewsFeed - 14 Apr 2009
Oasmia: FDA Grants Paclical(r) Orphan Drug Designation for Ovarian Cancer in the USA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Jan 2009
Marshall Edwards, Inc. Granted IND for Triphendiol
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Dec 2008
TransMolecular Receives Orphan Drug Designation for 131I-TM601 for the Treatment of Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Oct 2008
Abraxis BioScience and Specialised Therapeutics Australia Announce Approval to Market ABRAXANE for Metastatic Breast Cancer in Australia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 3 Oct 2008
Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 7 Aug 2008
SciClone Pharmaceuticals Appoints Jeffery Lange as Vice President, Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jul 2008
PhiloGene, Inc. Announces that VEGFb(TM) has been Granted Orphan Drug Designation by the FDA for the Treatment of Advanced Melanoma
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 14 Jul 2008
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in China
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Jul 2008
Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Jul 2008
Inovio Biomedical and VGX Pharmaceuticals Sign Merger Agreement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 2 Jun 2008
ABRAXANE(R) in Combination with Trastuzumab and Carboplatin Evaluated as First-Line Treatment for Patients with HER2-Positive Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2008
Combination Therapy of Solvent-Free ABRAXANE(R) and the Targeted Therapy Bevacizumab Evaluated as First-Line Treatment for Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 May 2008
Biogen Idec Celebrates 30 Years of Transforming Discovery into Care
Biopharmaceuticals
 HSMN NewsFeed - 23 Apr 2008
Abraxis BioScience Reports Promising Clinical Data in Advanced Pancreatic Cancer Using a Combination of nab-Paclitaxel (ABRAXANE(R)) and Gemcitabine (Gemzar(R))
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Apr 2008
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in Korea
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Mar 2008
Abraxis Bioscience Announces Filing of Marketing Application in Japan for ABRAXANE in the Treatment of Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Feb 2008
EpiCept Announces Non-Binding Opinion by European Regulatory Authority on Ceplene Marketing Application
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 22 Feb 2008
Adherex Receives Orphan Drug Designation for ADH-1 in Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Feb 2008
SciClone and Sigma-Tau Report Promising Interim Results From Phase 3 Hepatitis C Trial
Biopharmaceuticals
 HSMN NewsFeed - 7 Feb 2008
Abraxis Bioscience Establishes Global Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Jan 2008
FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Jan 2008
Abraxis Receives Approval from EU Commission to Market ABRAXANE for Metastatic Breast Cancer in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 Sep 2007
Roche's Tarceva(R) Delivers Longer Life for Lung Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Aug 2007
Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Aug 2007
Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2007
Progenics and Wyeth Announce FDA Has Accepted For Filing the New Drug Application for Subcutaneous Methylnaltrexone
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 May 2007
Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 26 Apr 2007
SciClone Acquires Clinical-Stage Pancreatic Cancer Compound
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 18 Apr 2007
Viragen Announces European Multiferon(R) Licensing Agreement
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 18 Apr 2007
Genta Announces New Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Mar 2007
Progenics and Wyeth Announce Submission of New Drug Application for the Subcutaneous Formulation of Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients Receiving Palliative Care
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 2 Feb 2007
Genta Completes Response to EMEA List of Outstanding Issues for Genasense(R) Marketing Authorization Application in Melanoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Jan 2007
Molecular Insight Pharmaceuticals, Inc. Acquires Malignant Melanoma Radiotherapeutic Drug Candidate from Bayer Schering Pharma
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 8 Jan 2007
Progenics Pharmaceuticals Expands Senior Management Team and Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Jan 2007
Vical Initiates Pivotal Phase 3 Trial of Allovectin-7(R) as First-line Therapy for Metastatic Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Dec 2006
SciClone Submits Regulatory Application for DC Bead in China
Biopharmaceuticals Drug Delivery Oncology Regulatory
 HSMN NewsFeed - 28 Dec 2006
SciClone and Sigma-Tau Complete Enrollment in Phase 3 Triple Therapy Hepatitis C Clinical Trial
Biopharmaceuticals
 HSMN NewsFeed - 22 Dec 2006
SciClone and Sigma-Tau Announce Positive Interim Survival Data From Large Phase 2 Malignant Melanoma Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Dec 2006
Wyeth and Progenics Initiate Second Global Phase 3 Trial of Intravenous Methylnaltrexone to Treat Post-operative Ileus
Biopharmaceuticals
 HSMN NewsFeed - 19 Dec 2006
TriPath Imaging Stockholders Approve Merger With Becton, Dickinson and Company
Diagnostics Mergers & Acquisitions
 HSMN NewsFeed - 29 Nov 2006
AVAX Technologies Launches Global Phase III Registration Clinical Trial of M-Vax in Metastatic Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Nov 2006
Alfred Rudolph, M.D. Is Leaving as Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Nov 2006
Synta Pharmaceuticals Announces FDA Fast Track Designation for STA-4783 in Metastatic Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Nov 2006
CombiMatrix Molecular Diagnostics Announces the Launch of Powerful New Melanoma Test
Diagnostics
 HSMN NewsFeed - 31 Oct 2006
GammaCan International, Announces Appointment of Lynn Schuchter M.D. to its Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Oct 2006
Genasense(R) Receives Orphan Drug Designation in Australia for Patients With Advanced Melanoma
Biopharmacetuicals Oncology Regulatory
 HSMN NewsFeed - 12 Oct 2006
TriPath Imaging Receives FDA 510(k) Clearance for p53 Application for Ventana Image Analysis System
Diagnostics Oncology FDA
 HSMN NewsFeed - 12 Oct 2006
AVAX Technologies Announces Special Protocol Assessment Agreement with FDA for a Phase III Clinical Trial of M-Vax in Metastatic Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Oct 2006
Plexxikon and Roche Enter Partnership to Develop Targeted Cancer Therapeutic Medicine PLX4032
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Oct 2006
Plexxikon Files IND Application for Targeted Cancer Therapeutic PLX4032
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Sep 2006
Progenics and Wyeth Initiate Global Phase 3 Clinical Program of Intravenous Methylnaltrexone to Treat Post-Operative Ileus
Biopharmaceuticals
 HSMN NewsFeed - 19 Jul 2006
TriPath Imaging, Inc. Announces Promotions of Johnny D. Powers, Ph.D. to President, TriPath Oncology and James D. Petrilla to Senior Vice President, Commercial Operations
Diagnostics Oncology Personnel
 HSMN NewsFeed - 17 Jul 2006
Wyeth and Progenics Announce Methylnaltrexone Receives FDA Fast Track Designation for Treatment of Postoperative Ileus
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 May 2006
SciClone Reports Final Results From Second ZADAXIN U.S. Phase 3 Hepatitis C Trial
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 163

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 163 additional stories matching:
malignant melanoma
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.